In Vitro Antiviral Activity of V-073 against Polioviruses |
| |
| Authors: | M. Steven Oberste Deborah Moore Barbara Anderson Mark A. Pallansch Daniel C. Pevear Marc S. Collett |
| |
| Affiliation: | Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia,1. Protez Pharmaceuticals, Inc., Malvern, Pennsylvania,2. ViroDefense Inc., Rockville, Maryland3. |
| |
| Abstract: | V-073, an enterovirus capsid inhibitor, was evaluated for its spectrum of antipoliovirus activity. V-073 inhibited all 45 polioviruses tested in a virus-induced cytopathic effect protection assay, with 50% effective concentration (EC50) values ranging from 0.003 to 0.126 μM. Ninety percent of the polioviruses tested were inhibited at EC50s of ≤0.076 μM (MIC90 = 32 ng/ml). V-073 is a promising antiviral candidate for the posteradication management of poliovirus incidents. |
| |
| Keywords: | |
|
|
